MA50800A - Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson - Google Patents

Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Info

Publication number: MA50800A
Authority: MA; Morocco
Prior art keywords: catecholamine; parkinson; disease; treatment; new
Prior art date: 2017-11-24

Application number

MA050800A

Other languages

English (en)

Inventor

Klaus Gjervig Jensen

Martin Juhl

Lisbet Kværnø

Jørgensen Morten

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-11-24

Filing date

2018-11-23

Publication date

2020-09-30

2018-11-23 Application filed by H Lundbeck As filed Critical H Lundbeck As

2020-09-30 Publication of MA50800A publication Critical patent/MA50800A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

MA050800A 2017-11-24 2018-11-23 Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson MA50800A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA201700674		2017-11-24

Publications (1)

Publication Number	Publication Date
MA50800A true MA50800A (fr)	2020-09-30

Family

ID=64661284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050800A MA50800A (fr)	2017-11-24	2018-11-23	Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson

Country Status (25)

Country	Link
US (5)	US10729710B2 (fr)
EP (1)	EP3713933B1 (fr)
JP (4)	JP7320507B2 (fr)
KR (1)	KR102712887B1 (fr)
CN (3)	CN111386267B (fr)
AR (1)	AR113908A1 (fr)
AU (2)	AU2018371193B2 (fr)
BR (1)	BR112019014981A2 (fr)
CA (1)	CA3082757A1 (fr)
CL (1)	CL2020001343A1 (fr)
CO (1)	CO2020006224A2 (fr)
CR (1)	CR20200225A (fr)
EA (1)	EA202090987A8 (fr)
EC (1)	ECSP20030074A (fr)
GE (2)	GEAP202215342A (fr)
IL (1)	IL274648B2 (fr)
JO (2)	JOP20200114B1 (fr)
MA (1)	MA50800A (fr)
MX (2)	MX2020005366A (fr)
PE (1)	PE20211290A1 (fr)
PH (1)	PH12020550631A1 (fr)
SG (1)	SG11202004461YA (fr)
TW (1)	TWI816716B (fr)
UA (1)	UA127575C2 (fr)
WO (1)	WO2019101917A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR113908A1 (es) *	2017-11-24	2020-06-24	H Lundbeck As	Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11168056B2 (en)	2019-05-20	2021-11-09	H. Lundbeck A/S	Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en)	2019-05-20	2021-09-07	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en)	2019-05-20	2021-09-28	H. Lundbeck A/S	Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en)	2019-05-20	2021-08-31	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113677675B (zh)	2019-05-21	2024-07-26	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
CN113727979B (zh) *	2019-05-21	2024-09-20	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
US12391650B2 (en)	2019-05-21	2025-08-19	H. Lundbeck A/S	Catecholamine prodrugs for use in the treatment of Parkinson's disease
EP3972600B1 (fr)	2019-05-21	2026-02-18	H. Lundbeck A/S	Promédicaments de carbamate de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
JP2023552699A (ja) *	2020-11-17	2023-12-19	ハー・ルンドベック・アクチエゼルスカベット	パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
AU2023259559A1 (en)	2022-04-25	2024-10-31	Integrative Research Laboratories Sweden Ab	NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
IL316452A (en)	2022-04-25	2024-12-01	Integrative Res Laboratories Sweden Ab	New esters of 1,2,3,4,4a,5,6,7,8,9,10,10a-dodecahydrobenzo[g]quinolin-6-ol compounds and their uses
WO2023208867A1 (fr)	2022-04-25	2023-11-02	Integrative Research Laboratories Sweden Ab	Nouveaux composés de 1,2,3,4,4a,5,8,9,10,10a-décahydrobenzo[g]quinolin-6(7h)-one et leurs utilisations
US20250361252A1 (en)	2022-06-15	2025-11-27	Ever Neuro Pharma Gmbh	Apomorphine prodrugs and uses thereof
WO2025078571A1 (fr)	2023-10-12	2025-04-17	Integrative Research Laboratories Sweden Ab	Nouveaux carbonates et carbamates de composés 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations
WO2025078574A1 (fr)	2023-10-12	2025-04-17	Integrative Research Laboratories Sweden Ab	Nouveaux esters de composés 1,2,3,4,4a,5,6,7,8,9,10,10a-dodécahydrobenzo[g]quinolin-6-ol et leurs utilisations

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3132171A (en)	1962-06-18	1964-05-05	Strong Cobb Arner Inc	3, 4-diphosphatophenyl-alanine and process for making same
US4543256A (en)	1982-03-17	1985-09-24	Northeastern University	(-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
LU88619I2 (fr)	1981-10-16	1995-07-10	Sandoz Ag	QUINAGOLIDE, éventuellement sous forme de sel, par exemple du chlorhydrate
FR2540112B1 (fr)	1983-02-01	1986-08-29	Sandoz Sa	Nouveaux derives de la benzo(g)quinoleine, leur preparation et leur utilisation comme medicaments
JPS60172975A (ja)	1984-02-15	1985-09-06	Sumitomo Chem Co Ltd	エリスロ−３−（３，４−メチレンジオキシフエニル）セリンの製造方法
GB2192394A (en)	1986-07-11	1988-01-13	Glaxo Group Ltd	Amine derivatives
IT1226727B (it)	1988-07-29	1991-02-05	Simes	Farmaci precursori della dopamina.
ES2070994T3 (es)	1989-04-20	1995-06-16	Zambon Spa	Profarmaco de dopamina.
WO1990012574A1 (fr)	1989-04-25	1990-11-01	Northeastern University	Composes agonistes de la dopamine
IT1271411B (it)	1993-09-14	1997-05-28	Zambon Spa	Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
US5955468A (en)	1993-12-21	1999-09-21	Sandoz Ltd.	Benzo G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
TW357143B (en)	1995-07-07	1999-05-01	Novartis Ag	Benzo[g]quinoline derivatives
IT1289979B1 (it)	1997-02-26	1998-10-19	Zambon Spa	5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
GB9902938D0 (en)	1999-02-10	1999-03-31	Novartis Ag	Organic compounds
CO5261532A1 (es)	1999-11-15	2003-03-31	Novartis Ag	Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
CN1471395A (zh)	2000-04-07	2004-01-28	��ҽҩƷ��޹�˾	阿扑吗啡衍生物及其使用方法
SE0001438D0 (sv)	2000-04-18	2000-04-18	Axon Chemicals Bv	New chemical compounds and their use in therapy
EP1320367A4 (fr)	2000-08-11	2007-01-17	Purdue Research Foundation	Methode de preparation de la dinapsoline
SE0002934D0 (sv)	2000-08-17	2000-08-17	Axon Biochemicals Bv	New aporphine esters and in their use in therapy
SE0102036D0 (sv)	2001-06-08	2001-06-08	Axon Biochemicals Bv	Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
PE20030240A1 (es)	2001-07-09	2003-04-16	Novartis Ag	DERIVADOS DE BENZO [g] QUINOLINA
JP2005504758A (ja)	2001-08-10	2005-02-17	パーデュー・リサーチ・ファウンデーション	キラル・ジナプソリン
EG24415A (en)	2002-03-07	2009-05-25	Novartis Ag	Quinoline derivatives
KR20050008658A (ko)	2002-03-19	2005-01-21	마이클 홀릭	아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
AU2003293423A1 (en)	2002-12-06	2004-06-30	Xenoport, Inc.	Carbidopa prodrugs and uses thereof
JP2007516292A (ja)	2003-12-23	2007-06-21	ダーファーマ，インコーポレイテッド	ドーパミン受容体結合化合物の共投与
WO2006012640A2 (fr)	2004-07-21	2006-02-02	Darpharma, Inc.	Procedes d'administration d'agonistes du recepteur de la dopamine
WO2006056604A1 (fr)	2004-11-25	2006-06-01	Evolva Ag	Derives de levodopa glycosyl, procedes de preparation et d'utilisation associes
TWI404702B (zh)	2007-08-31	2013-08-11	Lundbeck & Co As H	兒茶酚胺衍生物和其前藥
US20090124651A1 (en)	2007-08-31	2009-05-14	H. Lundbeck A/S	Catecholamine derivatives and prodrugs thereof
CN102131790A (zh)	2008-06-27	2011-07-20	H.隆德贝克有限公司	新型苯酚型和儿茶酚型胺及其前药
TW201035054A (en)	2009-02-27	2010-10-01	Lundbeck & Co As H	Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
TW201036949A (en) *	2009-02-27	2010-10-16	Lundbeck & Co As H	Treatment of dyskinesia related disorders
EP2557079A1 (fr)	2011-08-09	2013-02-13	Nestec S.A.	Synthèse de catéchine et conjugués d'épicatéchine
DE102011112496A1 (de)	2011-09-07	2013-03-07	Thanares GmbH	4-Methylcatecholderivate und deren Verwendung
CN102746351B (zh)	2012-07-23	2018-03-02	上海弈柯莱生物医药科技有限公司	灯盏花乙素及其类似物的制备方法
GB201319768D0 (en)	2013-11-08	2013-12-25	Glycosynth Ltd	Naphthalene derived chromogenic enzyme substrates
RU2021103000A (ru)	2014-10-21	2021-03-01	Эббви Инк.	Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
CN105218606B (zh)	2015-10-19	2017-12-01	昆明理工大学	一种制备灯盏乙素的方法
JP2019515908A (ja)	2016-04-20	2019-06-13	アッヴィ・インコーポレイテッド	カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
US9920342B2 (en)	2016-05-17	2018-03-20	Divi's Laboratories Limited	Process for the preparation of Droxidopa
AR113908A1 (es)	2017-11-24	2020-06-24	H Lundbeck As	Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11130775B2 (en)	2019-05-20	2021-09-28	H. Lundbeck A/S	Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en)	2019-05-20	2021-08-31	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en)	2019-05-20	2021-11-09	H. Lundbeck A/S	Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en)	2019-05-20	2021-09-07	H. Lundbeck A/S	Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113727979B (zh)	2019-05-21	2024-09-20	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
CN113677675B (zh)	2019-05-21	2024-07-26	H.隆德贝克有限公司	用于治疗帕金森病的新儿茶酚胺前药
EP3972600B1 (fr)	2019-05-21	2026-02-18	H. Lundbeck A/S	Promédicaments de carbamate de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US12391650B2 (en)	2019-05-21	2025-08-19	H. Lundbeck A/S	Catecholamine prodrugs for use in the treatment of Parkinson's disease
JP2023552699A (ja)	2020-11-17	2023-12-19	ハー・ルンドベック・アクチエゼルスカベット	パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
JP7693430B2 (ja) *	2021-07-15	2025-06-17	株式会社日立製作所	運行提案システム、及び運行提案作成方法

2018
- 2018-11-23 AR ARP180103436A patent/AR113908A1/es unknown
- 2018-11-23 TW TW107141799A patent/TWI816716B/zh active
- 2018-11-23 MX MX2020005366A patent/MX2020005366A/es unknown
- 2018-11-23 SG SG11202004461YA patent/SG11202004461YA/en unknown
- 2018-11-23 CA CA3082757A patent/CA3082757A1/fr active Pending
- 2018-11-23 CR CR20200225A patent/CR20200225A/es unknown
- 2018-11-23 GE GEAP202215342A patent/GEAP202215342A/en unknown
- 2018-11-23 CN CN201880075320.XA patent/CN111386267B/zh active Active
- 2018-11-23 GE GEAP201815342A patent/GEP20227446B/en unknown
- 2018-11-23 US US16/198,917 patent/US10729710B2/en active Active
- 2018-11-23 PE PE2020000566A patent/PE20211290A1/es unknown
- 2018-11-23 JP JP2020528199A patent/JP7320507B2/ja active Active
- 2018-11-23 CN CN202311564502.2A patent/CN117599073A/zh active Pending
- 2018-11-23 IL IL274648A patent/IL274648B2/en unknown
- 2018-11-23 MA MA050800A patent/MA50800A/fr unknown
- 2018-11-23 WO PCT/EP2018/082361 patent/WO2019101917A1/fr not_active Ceased
- 2018-11-23 BR BR112019014981A patent/BR112019014981A2/pt unknown
- 2018-11-23 UA UAA202003060A patent/UA127575C2/uk unknown
- 2018-11-23 EA EA202090987A patent/EA202090987A8/ru unknown
- 2018-11-23 KR KR1020207014479A patent/KR102712887B1/ko active Active
- 2018-11-23 EP EP18815537.8A patent/EP3713933B1/fr active Active
- 2018-11-23 AU AU2018371193A patent/AU2018371193B2/en active Active
- 2018-11-23 CN CN202311564635.XA patent/CN117653649A/zh active Pending
2020
- 2020-05-12 US US16/872,802 patent/US11110110B2/en active Active
- 2020-05-14 PH PH12020550631A patent/PH12020550631A1/en unknown
- 2020-05-17 JO JOJO/P/2020/0114A patent/JOP20200114B1/ar active
- 2020-05-20 CL CL2020001343A patent/CL2020001343A1/es unknown
- 2020-05-21 CO CONC2020/0006224A patent/CO2020006224A2/es unknown
- 2020-06-03 EC ECSENADI202030074A patent/ECSP20030074A/es unknown
- 2020-07-13 MX MX2022016276A patent/MX2022016276A/es unknown
2021
- 2021-07-28 US US17/386,686 patent/US11707476B2/en active Active
2023
- 2023-01-31 JP JP2023013012A patent/JP7320684B2/ja active Active
- 2023-03-21 AU AU2023201741A patent/AU2023201741A1/en not_active Abandoned
- 2023-06-06 US US18/330,293 patent/US12226428B2/en active Active
- 2023-07-24 JP JP2023119694A patent/JP2023145580A/ja active Pending
- 2023-07-24 JP JP2023119693A patent/JP7443606B2/ja active Active
- 2023-09-26 JO JOJO/P/2023/0235A patent/JOP20230235A1/ar unknown
2025
- 2025-01-15 US US19/021,529 patent/US20250381208A1/en active Pending

Also Published As

Publication number	Publication date
TWI816716B (zh)	2023-10-01
CN117599073A (zh)	2024-02-27
JP2023145580A (ja)	2023-10-11
EP3713933B1 (fr)	2026-03-25
AU2023201741A1 (en)	2023-04-20
CO2020006224A2 (es)	2020-05-29
EP3713933A1 (fr)	2020-09-30
JP7320684B2 (ja)	2023-08-03
US20240156851A1 (en)	2024-05-16
US12226428B2 (en)	2025-02-18
EA202090987A8 (ru)	2020-09-29
MX2020005366A (es)	2020-08-13
AU2018371193B2 (en)	2022-12-22
JOP20200114B1 (ar)	2024-04-18
US20220257623A1 (en)	2022-08-18
US20190160083A1 (en)	2019-05-30
GEP20227446B (en)	2022-12-12
PE20211290A1 (es)	2021-07-20
US20250381208A1 (en)	2025-12-18
JP2021504345A (ja)	2021-02-15
NZ764717A (en)	2024-08-30
EA202090987A1 (ru)	2020-08-07
US20200338102A1 (en)	2020-10-29
AR113908A1 (es)	2020-06-24
SG11202004461YA (en)	2020-06-29
KR20200092955A (ko)	2020-08-04
IL274648B1 (en)	2024-06-01
PH12020550631A1 (en)	2021-02-22
GEAP202215342A (en)	2022-07-11
JP7443606B2 (ja)	2024-03-05
JP2023055830A (ja)	2023-04-18
JOP20200114A1 (ar)	2020-05-17
BR112019014981A2 (pt)	2020-04-07
CN117653649A (zh)	2024-03-08
CN111386267B (zh)	2023-12-12
RU2020116419A (ru)	2021-12-27
JOP20230235A1 (ar)	2023-09-26
WO2019101917A1 (fr)	2019-05-31
JP7320507B2 (ja)	2023-08-03
TW201924693A (zh)	2019-07-01
US10729710B2 (en)	2020-08-04
US11707476B2 (en)	2023-07-25
AU2018371193A1 (en)	2020-06-11
KR102712887B1 (ko)	2024-10-02
CR20200225A (es)	2020-07-25
IL274648B2 (en)	2024-10-01
ECSP20030074A (es)	2020-07-31
IL274648A (en)	2020-06-30
JP2023145579A (ja)	2023-10-11
UA127575C2 (uk)	2023-10-18
CL2020001343A1 (es)	2020-09-25
CN111386267A (zh)	2020-07-07
US11110110B2 (en)	2021-09-07
CA3082757A1 (fr)	2019-05-31
MX2022016276A (es)	2023-02-09

Publication	Publication Date	Title
MA50800A (fr)	2020-09-30	Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA49402A (fr)	2020-04-22	Polynucléotides aadc pour le traitement de la maladie de parkinson
EP3405215A4 (fr)	2019-08-28	Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie
EP3820537A4 (fr)	2022-04-13	Vecteurs de thérapie génique pour le traitement de la maladie de danon
EP3528852A4 (fr)	2020-06-03	Méthodes et compositions pour le traitement de la maladie de fabry
MA52631A (fr)	2021-03-24	Compositions et méthodes pour le traitement de la maladie de parkinson
MA54792A (fr)	2021-12-01	Compositions et méthodes pour le traitement de la maladie de parkinson
EP3592841A4 (fr)	2021-01-06	Procédés et compositions de traitement de cancers à l'aide d'acides nucléiques antisens
MA50905A (fr)	2020-09-23	Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3600304A4 (fr)	2021-01-06	Alcaloïdes berbérine dans la prévention et/ou le traitement d'une maladie intestinale
EP3672587A4 (fr)	2021-05-19	Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA50233A (fr)	2020-07-22	Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
HUE059387T2 (hu)	2022-11-28	Parkinson-kór kezelése
EP3846821A4 (fr)	2022-05-25	Polythérapie destinée au traitement d'une maladie hépatique
EP3694579A4 (fr)	2021-07-07	Administration automatisée à base clinique de substances de traitement à l'oreille interne
EP3362096A4 (fr)	2019-06-12	Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques
EP3856168A4 (fr)	2022-07-06	Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
EP3833435A4 (fr)	2022-05-11	Détermination de la maladie de parkinson
EP4069700A4 (fr)	2023-05-17	Macrocycles destinés à être utilisés dans le traitement d'une maladie
EP3654961A4 (fr)	2021-04-21	Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine
EP3802568A4 (fr)	2022-07-13	Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés
EP3628008A4 (fr)	2021-04-28	Compositions et méthodes pour le traitement de la maladie d'alzheimer
EP3852722A4 (fr)	2022-08-03	Compositions et méthodes pour le traitement de la maladie de parkinson
EP3402778A4 (fr)	2019-12-18	Procédés et compositions médicamenteuses destinés au traitement de la maladie de lyme
EP3615022C0 (fr)	2023-06-07	Petites molécules organiques destinées à être utilisées dans le traitement de troubles neuroinflammatoires